Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) Sees Significant Decline in Short Interest

Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) was the target of a significant decline in short interest in January. As of January 31st, there was short interest totalling 642,400 shares, a decline of 55.7% from the January 15th total of 1,450,700 shares. Based on an average trading volume of 100 shares, the days-to-cover ratio is presently 6,424.0 days.

Swedish Orphan Biovitrum AB (publ) Price Performance

BIOVF remained flat at $30.48 during trading on Friday. Swedish Orphan Biovitrum AB has a 12 month low of $22.87 and a 12 month high of $32.25. The business’s fifty day simple moving average is $28.73 and its 200-day simple moving average is $28.84. The firm has a market capitalization of $10.85 billion, a price-to-earnings ratio of 51.66 and a beta of 0.53. The company has a debt-to-equity ratio of 0.30, a quick ratio of 0.49 and a current ratio of 0.73.

Wall Street Analysts Forecast Growth

Separately, Barclays raised Swedish Orphan Biovitrum AB (publ) to a “strong-buy” rating in a report on Wednesday, January 8th.

About Swedish Orphan Biovitrum AB (publ)

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); VONJO for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis; Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still’s disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection.